Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), discusses the most important takeaways from recent guidance on type 1 diabetes from the ADA and European Association for the Study of Diabetes (EASD).
Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), discusses the most important takeaways from recent guidance on type 1 diabetes from the ADA and European Association for the Study of Diabetes (EASD).
Transcript
What are the most important takeaways from the recent guidance on type 1 diabetes from ADA and EASD?
The recent consensus report by the American Diabetes Association and our colleagues at EASD, the European organization, it’s the first comprehensive look at the management of type 1 diabetes, and it covers really soup to nuts. I mean, it covers everything. But just some highlights are newer information about how to make the diagnosis. I think we're all familiar, but the important role of [anti–glutamic acid decarboxylase] anti-gad antibodies, for example, was the first sort of screening antibody to use, and then the role of that versus measuring C-peptide.
It also helps to define what the targets should be for glycemic control for people with type 1 diabetes, and extends that to the ambulatory glucose profile, and how to use that information from a continuous glucose monitor to be able to help manage individuals with diabetes. It then takes time to really go into the importance of mental health, and how that often can be an issue that needs to be addressed for people with type 1 diabetes, and the important role of diabetes self-management, education and support, and what are the topics that need to be covered for people with diabetes.
And then, of course, medical treatment in terms of insulin—the different insulin regimens that one can use, some guidance or dosage, some pluses and minuses of those different regimens. And then even some of the adjunct therapy that has been proposed for people with type 1 diabetes, the data associated with that. So really, it's a comprehensive look at the management of type 1 diabetes that I think clinicians will find really valuable.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More